320 related articles for article (PubMed ID: 35199244)
1. Impacts of bisphosphonates on the bone and its surrounding tissues: mechanistic insights into medication-related osteonecrosis of the jaw.
Srivichit B; Thonusin C; Chattipakorn N; Chattipakorn SC
Arch Toxicol; 2022 May; 96(5):1227-1255. PubMed ID: 35199244
[TBL] [Abstract][Full Text] [Related]
2. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ?
Hasegawa T; Kawakita A; Ueda N; Funahara R; Tachibana A; Kobayashi M; Kondou E; Takeda D; Kojima Y; Sato S; Yanamoto S; Komatsubara H; Umeda M; Kirita T; Kurita H; Shibuya Y; Komori T;
Osteoporos Int; 2017 Aug; 28(8):2465-2473. PubMed ID: 28451732
[TBL] [Abstract][Full Text] [Related]
3. Etiopathogenesis of medication-related osteonecrosis of the jaws: a review.
Bassan Marinho Maciel G; Marinho Maciel R; Linhares Ferrazzo K; Cademartori Danesi C
J Mol Med (Berl); 2024 Mar; 102(3):353-364. PubMed ID: 38302741
[TBL] [Abstract][Full Text] [Related]
4. MRONJ risk of adjuvant bisphosphonates in early stage breast cancer.
Patel V; Mansi J; Ghosh S; Kwok J; Burke M; Reilly D; Nizarali N; Sproat C; Chia K
Br Dent J; 2018 Jan; 224(2):74-79. PubMed ID: 29242516
[TBL] [Abstract][Full Text] [Related]
5. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).
Otto S; Aljohani S; Fliefel R; Ecke S; Ristow O; Burian E; Troeltzsch M; Pautke C; Ehrenfeld M
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34065104
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Segmentation Analysis of the Radiological Changes by Using ITK-SNAP: Risk Assessment of the Severity and Recurrence of Medication-related Osteonecrosis of the Jaw.
Zhou YQ; Son GH; Shi YQ; Yu YJ; Li MY; Zhang Q; Zou DH; Zhang ZY; Yang C; Wang SY
Int J Med Sci; 2021; 18(10):2209-2216. PubMed ID: 33859529
[No Abstract] [Full Text] [Related]
7. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
8. Medication-related osteonecrosis of the jaw: A disease of significant importance for older patients.
Boston B; Ipe D; Capitanescu B; Gresita A; Hamlet S; Love R; Hadjiargyrou M; Huang CL; Nusem I; Miroiu RI; Popa-Wagner A; Warnke PH; Petcu EB
J Am Geriatr Soc; 2023 Aug; 71(8):2640-2652. PubMed ID: 37224415
[TBL] [Abstract][Full Text] [Related]
9. Osteoporosis therapy in patients with inflammatory rheumatic diseases and osteonecrosis of the jaw.
Schwaneck EC; Streit A; Krone M; Hartmann S; Müller-Richter U; Kübler AC; Gadeholt O; Schmalzing M; Tony HP; Brands RC
Z Rheumatol; 2020 Mar; 79(2):203-209. PubMed ID: 30796524
[TBL] [Abstract][Full Text] [Related]
10. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.
Otto S; Pautke C; Van den Wyngaert T; Niepel D; Schiødt M
Cancer Treat Rev; 2018 Sep; 69():177-187. PubMed ID: 30055439
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials.
Holtmann H; Lommen J; Kübler NR; Sproll C; Rana M; Karschuck P; Depprich R
J Int Med Res; 2018 Oct; 46(10):4277-4296. PubMed ID: 30091399
[TBL] [Abstract][Full Text] [Related]
12. Immune Dysfunction in Medication-Related Osteonecrosis of the Jaw.
Roato I; Mauceri R; Notaro V; Genova T; Fusco V; Mussano F
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175652
[TBL] [Abstract][Full Text] [Related]
13. Osteoclast profile of medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis.
Gross C; Weber M; Creutzburg K; Möbius P; Preidl R; Amann K; Wehrhan F
J Transl Med; 2017 Jun; 15(1):128. PubMed ID: 28587628
[TBL] [Abstract][Full Text] [Related]
14. Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid.
Mozzati M; Martinasso G; Maggiora M; Scoletta M; Zambelli M; Carossa S; Oraldi M; Muzio G; Canuto RA
Clin Oral Investig; 2013 May; 17(4):1259-66. PubMed ID: 22864527
[TBL] [Abstract][Full Text] [Related]
15. The role of bisphosphonates in medical oncology and their association with jaw bone necrosis.
Eid A; Atlas J
Oral Maxillofac Surg Clin North Am; 2014 May; 26(2):231-7. PubMed ID: 24794267
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Medication-Related Osteonecrosis of the Jaw: Controversies in Causality and Therapy.
Halpern LR; Adams DR
Dent Clin North Am; 2024 Jan; 68(1):67-85. PubMed ID: 37951638
[TBL] [Abstract][Full Text] [Related]
17. Emerging antiresorptive medications and their potential implications for dental surgeries.
Aminoshariae A; Donaldson M; Horan M; Mackey SA; Kulild JC; Baur D
J Am Dent Assoc; 2022 Jul; 153(7):649-658. PubMed ID: 35277242
[TBL] [Abstract][Full Text] [Related]
18. Medication-related osteonecrosis of the jaw: A literature review and update.
Kuroshima S; Al-Omari FA; Sasaki M; Sawase T
Genesis; 2022 Sep; 60(8-9):e23500. PubMed ID: 36106755
[TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis of the jaw induced by bisphosphonates therapy in bone metastases patient: Case report and literature review.
Hao L; Tian Z; Li S; Yan K; Xue Y
Oral Oncol; 2022 May; 128():105852. PubMed ID: 35439709
[TBL] [Abstract][Full Text] [Related]
20. [Bisphosphonate-related osteonecrosis of the jaw].
Atanes-Bonome P; Atanes-Bonome A; Ríos-Lage P; Atanes-Sandoval AD
Semergen; 2014 Apr; 40(3):143-8. PubMed ID: 24001573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
